Our exploratory studies demonstrated that our GlyHealth-Index test for measurement of general chronic inflammation is superior to other commonly used biomarkers to detect and monitor chronic levels of inflammation in patients.
GlyHealth Index (GHI) and high-sensitivity C-Reactive Protein (hsCRP) were tested using a group of over 400 people which included individuals with inflammatory bowel disease (IBD) and control samples. Receiver operating characteristic (ROC) analyses of the cohort show that the GHI and clinical markers were assessed to predict inflammation.
The GHI marker depicted an area under the curve (AUC) of 0.76 in the ROC analyses shown in Panel A. hsCRP marker gave an AUC of 0.60 for prediction of inflammation.
Based on this study, the Immunofrailty concept and test has been developed.
I you want to join our Immunofrailty test